ALBANESI, MARCELLO
 Distribuzione geografica
Continente #
NA - Nord America 1.176
EU - Europa 563
AS - Asia 178
SA - Sud America 7
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.927
Nazione #
US - Stati Uniti d'America 1.175
DE - Germania 177
IT - Italia 137
CN - Cina 119
SE - Svezia 95
RU - Federazione Russa 59
GB - Regno Unito 56
SG - Singapore 43
FR - Francia 10
FI - Finlandia 8
BR - Brasile 7
BE - Belgio 6
IN - India 6
VN - Vietnam 6
PL - Polonia 5
CZ - Repubblica Ceca 2
ES - Italia 2
IE - Irlanda 2
TR - Turchia 2
ZA - Sudafrica 2
AZ - Azerbaigian 1
CH - Svizzera 1
DK - Danimarca 1
EU - Europa 1
JP - Giappone 1
LT - Lituania 1
NL - Olanda 1
PA - Panama 1
Totale 1.927
Città #
Fairfield 164
Chandler 154
Houston 118
Ashburn 117
Nyköping 86
Seattle 68
Woodbridge 64
Wilmington 54
Cambridge 47
Ann Arbor 46
New York 37
Beijing 32
Singapore 26
Dearborn 22
Lawrence 20
Bari 19
Roxbury 19
Nanjing 14
Des Moines 13
Brooklyn 11
Boardman 9
Redwood City 9
San Diego 9
Shenyang 8
Helsinki 7
Inglewood 7
Brussels 6
Changsha 6
Milan 6
Santa Clara 6
Dong Ket 5
Jiaxing 5
Martina Franca 5
Modugno 5
Paris 4
Pune 4
San Francisco 4
Shenzhen 4
Cutrofiano 3
Edinburgh 3
Jinan 3
Kunming 3
London 3
Los Angeles 3
Melendugno 3
Munich 3
Nanchang 3
Princeton 3
Shanghai 3
Turi 3
Washington 3
Wuhan 3
Altamura 2
Barcelona 2
Cerignola 2
Dublin 2
Genoa 2
Grumo Appula 2
Guangzhou 2
Hangzhou 2
Hebei 2
Norwalk 2
Nuremberg 2
Olomouc 2
Pomezia 2
Acton 1
Adana 1
Amsterdam 1
Arzano 1
Belo Horizonte 1
Blumenau 1
Bocale 1
Bolzano 1
Brindisi 1
Casamassima 1
Chicago 1
Chiswick 1
Clifton 1
Conversano 1
Esslingen am Neckar 1
Fuzhou 1
Gauteng 1
Handan 1
Hefei 1
Ho Chi Minh City 1
Hounslow 1
Jaboatão dos Guararapes 1
Jacksonville 1
Jinhua 1
Lucera 1
Lugano 1
Miami 1
Midrand 1
Nardò 1
Niva 1
Nocera Inferiore 1
Oriximiná Municipality 1
Palermo 1
Pilar do Sul 1
Piracuruca 1
Totale 1.343
Nome #
Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects 161
Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study 155
Reazioni ritardate a farmaci: dal test di proliferazione linfocitaria alla desensibilizzazione. 143
A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy 108
Is immunotherapy with fungal vaccines effective? 107
null 101
Wasp immunotherapy induced long-term and IgG4-independent protection 87
Test di proliferazione linfocitaria nella diagnosi delle reazioni ritardate a farmaci 81
Safety and treatment compliance of subcutaneous immunotherapy: A 30-year retrospective study 81
Cost-effectiveness of grass pollen allergen immunotherapy in adults 78
null 74
Studi su Omalizumab nella terapia dell'asma severo. Valutazione degli effetti sulla risposta immunologica IgE in vivo. Valutazione della tollerabilità. 72
null 72
null 68
Omalizumab in long-term treatment of refractory chronic spontaneus urticaria:effects of discontinuation 67
null 64
Desensitization in Iron Product Allergy 63
Immunological characterization of onion (Allium cepa) allergy 49
null 48
Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2-year real-life study 47
Benralizumab improves patient reported outcomes and functional parameters in difficult-to-treat patients with severe asthma: Data from a real-life cohort 43
Desensitization for immediate hypersensitivity to oral dimethyl fumarate (Tecfidera) 40
A desensitization protocol for delayed allergy to cytarabine: Analysis of two cases 35
Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study 33
Delayed allergy to acyclovir revealed by lymphocyte proliferation test 31
Safety of measles, mumps, and rubella vaccine in egg allergy: in vivo and in vitro management 30
Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review 24
Importance of Specific IgE/Total IgE Ratio in Disambiguating Amoxicillin Allergy Diagnosis in a Real-Life Setting 24
Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: A case report 21
Totale 2.007
Categoria #
all - tutte 8.582
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.582


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020350 0 0 0 0 30 76 43 37 33 46 53 32
2020/2021361 25 52 19 45 43 36 21 38 15 30 13 24
2021/2022181 10 7 6 4 3 21 5 16 8 18 28 55
2022/2023362 28 75 32 20 36 47 7 31 70 2 8 6
2023/2024173 7 22 11 11 9 63 21 8 1 2 4 14
2024/2025113 32 3 35 22 21 0 0 0 0 0 0 0
Totale 2.007